My NCBI | Sign In
RSS Settings
  • Search:

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 1274

    1.

    Differential effects of metformin and troglitazone on cardiovascular risk factors in patients with type 2 diabetes.

    Chu NV, Kong AP, Kim DD, Armstrong D, Baxi S, Deutsch R, Caulfield M, Mudaliar SR, Reitz R, Henry RR, Reaven PD.

    Diabetes Care. 2002 Mar;25(3):542-9. Erratum in: Diabetes Care 2002 May;25(5):947. PMID: 11874944 [PubMed - indexed for MEDLINE]Related articlesFree article

    2.

    The effect of a thiazolidinedione drug, troglitazone, on glycemia in patients with type 2 diabetes mellitus poorly controlled with sulfonylurea and metformin. A multicenter, randomized, double-blind, placebo-controlled trial.

    Yale JF, Valiquett TR, Ghazzi MN, Owens-Grillo JK, Whitcomb RW, Foyt HL.

    Ann Intern Med. 2001 May 1;134(9 Pt 1):737-45.PMID: 11329231 [PubMed - indexed for MEDLINE]Related articlesFree article

    3.

    A comparison of troglitazone and metformin on insulin requirements in euglycemic intensively insulin-treated type 2 diabetic patients.

    Yu JG, Kruszynska YT, Mulford MI, Olefsky JM.

    Diabetes. 1999 Dec;48(12):2414-21.PMID: 10580431 [PubMed - indexed for MEDLINE]Related articlesFree article

    4.

    Troglitazone monotherapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, controlled study. The Troglitazone Study Group.

    Fonseca VA, Valiquett TR, Huang SM, Ghazzi MN, Whitcomb RW.

    J Clin Endocrinol Metab. 1998 Sep;83(9):3169-76.PMID: 9745421 [PubMed - indexed for MEDLINE]Related articlesFree article

    5.

    Troglitazone, an insulin action enhancer, improves metabolic control in NIDDM patients. Troglitazone Study Group.

    Kumar S, Boulton AJ, Beck-Nielsen H, Berthezene F, Muggeo M, Persson B, Spinas GA, Donoghue S, Lettis S, Stewart-Long P.

    Diabetologia. 1996 Jun;39(6):701-9. Erratum in: Diabetologia 1996 Oct;39(10):1245. PMID: 8781766 [PubMed - indexed for MEDLINE]Related articles

    6.

    Effects of troglitazone on blood concentrations of plasminogen activator inhibitor 1 in patients with type 2 diabetes and in lean and obese normal subjects.

    Kruszynska YT, Yu JG, Olefsky JM, Sobel BE.

    Diabetes. 2000 Apr;49(4):633-9.PMID: 10871202 [PubMed - indexed for MEDLINE]Related articlesFree article

    7.

    Lipid effects of glyburide/metformin tablets in patients with type 2 diabetes mellitus with poor glycemic control and dyslipidemia in an open-label extension study.

    Dailey GE 3rd, Mohideen P, Fiedorek FT.

    Clin Ther. 2002 Sep;24(9):1426-38.PMID: 12380634 [PubMed - indexed for MEDLINE]Related articles

    8.

    Troglitazone in combination with sulfonylurea restores glycemic control in patients with type 2 diabetes. The Troglitazone Study Group.

    Horton ES, Whitehouse F, Ghazzi MN, Venable TC, Whitcomb RW.

    Diabetes Care. 1998 Sep;21(9):1462-9.PMID: 9727892 [PubMed - indexed for MEDLINE]Related articlesFree article

    9.

    Troglitazone add-on therapy to a combination of sulfonylureas plus metformin achieved and sustained effective diabetes control.

    Gavin LA, Barth J, Arnold D, Shaw R.

    Endocr Pract. 2000 Jul-Aug;6(4):305-10.PMID: 11242607 [PubMed - indexed for MEDLINE]Related articles

    10.

    Cardiac and glycemic benefits of troglitazone treatment in NIDDM. The Troglitazone Study Group.

    Ghazzi MN, Perez JE, Antonucci TK, Driscoll JH, Huang SM, Faja BW, Whitcomb RW.

    Diabetes. 1997 Mar;46(3):433-9.PMID: 9032099 [PubMed - indexed for MEDLINE]Related articles

    11.

    Effects of troglitazone on insulin action and cardiovascular risk factors in patients with non-insulin-dependent diabetes.

    Sironi AM, Vichi S, Gastaldelli A, Pecori N, Anichini R, Foot E, Seghieri G, Ferrannini E.

    Clin Pharmacol Ther. 1997 Aug;62(2):194-202.PMID: 9284856 [PubMed - indexed for MEDLINE]Related articles

    12.

    Effects of metformin on insulin resistance, risk factors for cardiovascular disease, and plasminogen activator inhibitor in NIDDM subjects. A study of two ethnic groups.

    Nagi DK, Yudkin JS.

    Diabetes Care. 1993 Apr;16(4):621-9.PMID: 8462390 [PubMed - indexed for MEDLINE]Related articles

    13.

    Effect of metformin treatment on multiple cardiovascular disease risk factors in patients with type 2 diabetes mellitus.

    Abbasi F, Chu JW, McLaughlin T, Lamendola C, Leary ET, Reaven GM.

    Metabolism. 2004 Feb;53(2):159-64.PMID: 14767866 [PubMed - indexed for MEDLINE]Related articles

    14.

    The effects of high- and medium-dose metformin therapy on cardiovascular risk factors in patients with type II diabetes.

    Grant PJ.

    Diabetes Care. 1996 Jan;19(1):64-6.PMID: 8720537 [PubMed - indexed for MEDLINE]Related articles

    15.

    Primary, secondary, tertiary, and quaternary treatment with troglitazone in type 2 diabetes mellitus in an outpatient clinical practice.

    Hershon KS, Hershon PM.

    Endocr Pract. 2000 Jan-Feb;6(1):20-5.PMID: 11419922 [PubMed - indexed for MEDLINE]Related articles

    16.

    Troglitazone but not metformin restores insulin-stimulated phosphoinositide 3-kinase activity and increases p110beta protein levels in skeletal muscle of type 2 diabetic subjects.

    Kim YB, Ciaraldi TP, Kong A, Kim D, Chu N, Mohideen P, Mudaliar S, Henry RR, Kahn BB.

    Diabetes. 2002 Feb;51(2):443-8.PMID: 11812753 [PubMed - indexed for MEDLINE]Related articlesFree article

    17.

    Repaglinide/troglitazone combination therapy: improved glycemic control in type 2 diabetes.

    Raskin P, Jovanovic L, Berger S, Schwartz S, Woo V, Ratner R.

    Diabetes Care. 2000 Jul;23(7):979-83.PMID: 10895850 [PubMed - indexed for MEDLINE]Related articlesFree article

    18.

    Peroxisome proliferator-activated receptor-gamma agonist increases both low-density lipoprotein cholesterol particle size and small high-density lipoprotein cholesterol in patients with type 2 diabetes independent of diabetic control.

    Bavirti S, Ghanaat F, Tayek JA.

    Endocr Pract. 2003 Nov-Dec;9(6):487-93.PMID: 14715475 [PubMed - indexed for MEDLINE]Related articles

    19.

    Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus.

    Inzucchi SE, Maggs DG, Spollett GR, Page SL, Rife FS, Walton V, Shulman GI.

    N Engl J Med. 1998 Mar 26;338(13):867-72.PMID: 9516221 [PubMed - indexed for MEDLINE]Related articlesFree article

    20.

    Comparison of insulin monotherapy and combination therapy with insulin and metformin or insulin and troglitazone in type 2 diabetes.

    Strowig SM, Avilés-Santa ML, Raskin P.

    Diabetes Care. 2002 Oct;25(10):1691-8.PMID: 12351463 [PubMed - indexed for MEDLINE]Related articlesFree article

    Supplemental Content

    Filter your results:

    Find related data

    Recent activity